Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 381
interventional 328
Observational 50
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 124
Biological 38
Drug|Other 21
Biological|Drug 20
Drug|Procedure 18
Biological|Drug|Procedure|Radiation 14
Biological|Drug|Procedure 10
Biological|Drug|Other 8
Biological|Other 7
Drug|Procedure|Radiation 7
Drug|Radiation 7
Device 5
Procedure 5
Radiation 5
Drug|Genetic 4
Drug|Other|Procedure 3
Other 3
Biological|Device|Drug 2
Biological|Drug|Other|Procedure|Radiation 2
Biological|Procedure|Radiation 2
Other|Procedure 2
Procedure|Radiation 2
Behavioral|Device|Drug 1
Behavioral|Drug|Genetic|Other|Procedure|Radiation 1
Biological|Device|Drug|Other 1
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Genetic 1
Biological|Drug|Other|Procedure 1
Biological|Drug|Radiation 1
Biological|Procedure 1
Biological|Radiation 1
Device|Drug 1
Diagnostic Test 1
Diagnostic Test|Drug|Radiation 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Other|placebo|Procedure 1
Drug|Other|Procedure|Radiation 1
Drug|placebo 1
Genetic|Other|Radiation 1
Genetic|Procedure 1
Other|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 205
United States|Canada 21
United States|Puerto Rico 11
United States|Australia|Canada 10
France 9
Korea, Republic of 6
Germany 5
China 4
United Kingdom 4
United States|Australia|Canada|Netherlands|New Zealand|Puerto Rico|Switzerland 4
Austria|Belgium|Denmark|France|Italy|Norway|Portugal|Spain|Sweden|Switzerland|United Kingdom 3
NA 3
United States|Australia 3
Argentina 2
United States|Australia|Canada|New Zealand|Puerto Rico 2
Australia|Austria|Belgium|Czechia|Denmark|France|Greece|Hungary|Ireland|Israel|Italy|Norway|Poland|Portugal|Slovakia|Slovenia|Spain|Sweden|Switzerland|United Kingdom 1
Austria 1
Austria|Belgium|Denmark|France|Germany|Italy|Norway|Portugal|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|France|Ireland|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|Israel|Italy|Norway|Spain|Sweden|Switzerland 1
Austria|France|Germany|Israel|Italy|Spain|United Kingdom 1
Austria|France|Italy|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Germany 1
Austria|Germany|Italy 1
Belarus 1
Belgium|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Spain|United Kingdom 1
Canada 1
France|Germany|Italy|United Kingdom 1
France|Ireland|United Kingdom 1
France|United States|Australia|Canada|Italy|United Kingdom 1
Germany|Netherlands|Switzerland 1
Germany|Switzerland 1
Italy 1
Singapore 1
Spain 1
Spain|Sweden|Austria|Belgium|Denmark|France|Italy|Norway|Portugal|Switzerland|United Kingdom 1
Sweden 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Japan|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Netherlands|Switzerland|United Kingdom 1
United States|Australia|Canada|Israel 1
United States|Australia|Canada|New Zealand 1
United States|Australia|Canada|New Zealand|Puerto Rico|Saudi Arabia 1
United States|Australia|Canada|New Zealand|Puerto Rico|Switzerland 1
United States|Canada|Australia|Netherlands|New Zealand|Puerto Rico 1
United States|Canada|Denmark|Germany|Hong Kong|Spain|United Kingdom 1
United States|Canada|France|Italy|Spain|Switzerland|United Kingdom 1
United States|Canada|France|Netherlands|Spain|United Kingdom 1
United States|Canada|France|United Kingdom 1
United States|Canada|Puerto Rico 1
United States|Denmark|Spain 1
United States|Lebanon 1

Sites per Study

Site_count Study_Count
1 168
2 19
3 8
4 7
5 4
6 8
7 7
8 4
9 2
10 4
11 5
12 9
13 8
14 3
15 6
17 2
18 2
19 1
20 2
21 1
22 1
23 3
24 2
25 1
26 2
27 2
28 1
30 1
32 1
33 1
35 1
36 2
37 1
38 1
40 1
44 1
59 1
61 1
69 1
71 1
76 2
81 1
87 1
94 1
96 1
105 2
106 1
111 2
112 1
113 1
114 1
116 1
117 1
118 1
121 1
126 1
128 1
140 1
157 1
161 1
167 1
189 1
190 1
197 1
213 1
226 1
228 1
235 2

Phase

Phase Study_Count
Phase 1 124
Phase 2 111
Phase 1/Phase 2 32
N/A 30
Phase 3 23
Early Phase 1 5
Phase 4 2
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 185
2 40
3 17
4 5
5 3
6 1
7 1
9 1
10 3
11 1
12 2
NA 69

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 12.0 6.0000 1.00000 5.00000 3.00000 32 100.0000 100.00
1st Qu. 15.0 20.0000 18.00000 27.25000 34.00000 32 232.2500 176.25
Median 20.0 44.0000 26.00000 43.00000 50.00000 32 497.5000 252.50
Mean 23.8 101.1429 33.81197 95.39286 99.21649 32 660.9545 252.50
3rd Qu. 20.0 136.2500 36.00000 145.75000 105.00000 32 771.2500 328.75
Max. 52.0 600.0000 165.00000 352.00000 1500.00000 32 3300.0000 405.00

Trial Group Type

group_type Group_Count
Experimental 389
NA 69
Active Comparator 21
Other 21
Placebo Comparator 3
No Intervention 2
Sham Comparator 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 208
NA 53
Parallel Assignment 49
Sequential Assignment 11
Crossover Assignment 4
Factorial Assignment 3

Primary Purpose

primary_purpose Study_Count
Treatment 288
Supportive Care 18
Diagnostic 10
Prevention 4
Basic Science 2
Other 2
Screening 2
Device Feasibility 1
NA 1

Observational Studies

Studies by Country

Country Study_Count
United States 25
NA 12
United States|Canada 3
Canada 2
Taiwan 2
Brazil 1
Egypt 1
United States|Australia|Canada 1
United States|Australia|Canada|Netherlands|New Zealand|Puerto Rico|Saudi Arabia|Switzerland 1
United States|Australia|Canada|New Zealand 1
United States|Canada|Puerto Rico|Switzerland 1

Sites per Study

Site_count Study_Count
1 37
2 2
3 1
4 1
9 1
11 1
14 1
31 1
45 1
66 1
94 1
153 1
259 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 75.500
Median 121.000
Mean 940.617
3rd Qu 450.000
Max 10000.000

Observation Model

observational_model Study_Count
Cohort 26
Case-Only 13
NA 5
Case Control 3
Family-Based 2
Other 1

Time Perspective

time_perspective Study_Count
Prospective 22
Retrospective 17
NA 5
Cross-Sectional 3
Other 3

Registries

Studies by Country

Country Study_Count
United States 2
Austria|France|Germany|Italy|Poland|Spain|United Kingdom 1

Sites per Study

Site_count Study_Count
3 1
5 1
13 1

Enrollment Metrics

Measure Registries
Min 101.0
1st Qu 113.0
Median 125.0
Mean 142.0
3rd Qu 162.5
Max 200.0

Registry Model

observational_model Study_Count
Cohort 2
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
10 Years 2
99 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04195555 Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT04195555 Recruiting National Cancer Institute (NCI) 2025-12-31
NCT04106219 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT04106219 Recruiting Eli Lilly and Company 2024-04-17
NCT03698994 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03698994 Recruiting National Cancer Institute (NCI) 2025-12-31
NCT03526250 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03526250 Recruiting National Cancer Institute (NCI) 2025-06-30
NCT03373097 Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT03373097 Recruiting Bambino Gesù Hospital and Research Institute 2024-12-31
NCT03363373 Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow https://ClinicalTrials.gov/show/NCT03363373 Recruiting Y-mAbs Therapeutics 2024-11-30
NCT03294954 GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT03294954 Recruiting Baylor College of Medicine 2021-09-01
NCT03291080 Oral Liquid 13-cis-retinoic Acid (13-CRA) https://ClinicalTrials.gov/show/NCT03291080 Completed Nova Laboratories Limited 2019-09-12
NCT03275402 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases https://ClinicalTrials.gov/show/NCT03275402 Recruiting Y-mAbs Therapeutics 2020-12-31
NCT03273712 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) https://ClinicalTrials.gov/show/NCT03273712 Recruiting University of Iowa 2020-01-31
NCT03242603 Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells https://ClinicalTrials.gov/show/NCT03242603 Recruiting National University Hospital, Singapore 2019-08-15
NCT03236857 A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies https://ClinicalTrials.gov/show/NCT03236857 Recruiting AbbVie 2022-04-07
NCT03189706 Study of Chemoimmunotherapy for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT03189706 Recruiting Memorial Sloan Kettering Cancer Center 2021-06-30
NCT03165292 Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy https://ClinicalTrials.gov/show/NCT03165292 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2023-06-30
NCT03126916 Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma https://ClinicalTrials.gov/show/NCT03126916 Recruiting Children’s Oncology Group 2026-09-30
NCT03107988 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) https://ClinicalTrials.gov/show/NCT03107988 Recruiting New Approaches to Neuroblastoma Therapy Consortium 2020-05-31
NCT03061656 Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT03061656 Active, not recruiting Samsung Medical Center 2013-12-31
NCT03042429 Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients https://ClinicalTrials.gov/show/NCT03042429 Completed University of Cologne 2016-12-31
NCT03042416 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety https://ClinicalTrials.gov/show/NCT03042416 Recruiting University of Alberta 2021-12-31
NCT03033303 A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT03033303 Recruiting Memorial Sloan Kettering Cancer Center 2022-06-30
NCT03233204 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03233204 Recruiting National Cancer Institute (NCI) 2024-09-30
NCT02998983 Racotumomab in Patients With High-risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02998983 Recruiting Laboratorio Elea Phoenix S.A. 2020-12-31
NCT02982941 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors https://ClinicalTrials.gov/show/NCT02982941 Completed MacroGenics 2019-05-22
NCT02933333 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor https://ClinicalTrials.gov/show/NCT02933333 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-08-30
NCT02924324 Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients https://ClinicalTrials.gov/show/NCT02924324 Completed Memorial Sloan Kettering Cancer Center 2019-11-30
NCT02919046 Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children https://ClinicalTrials.gov/show/NCT02919046 Recruiting Sinobioway Cell Therapy Co., Ltd. 2020-09-30
NCT02914405 Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT02914405 Recruiting University Hospital Southampton NHS Foundation Trust 2020-05-31
NCT02909777 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma https://ClinicalTrials.gov/show/NCT02909777 Recruiting Dana-Farber Cancer Institute 2020-10-31
NCT02864563 Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification https://ClinicalTrials.gov/show/NCT02864563 Recruiting Institut Curie 2021-12-31
NCT03220035 Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03220035 Recruiting National Cancer Institute (NCI) 2023-12-31
NCT03213704 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03213704 Recruiting National Cancer Institute (NCI) 2024-09-30
NCT02786719 High-Risk Neuroblastoma Chemotherapy Without G-CSF https://ClinicalTrials.gov/show/NCT02786719 Completed Baylor College of Medicine 2019-02-05
NCT02780128 Next Generation Personalized Neuroblastoma Therapy https://ClinicalTrials.gov/show/NCT02780128 Recruiting Children’s Hospital of Philadelphia 2021-07-31
NCT02771743 Response-based Treatment of High-risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02771743 Recruiting Samsung Medical Center 2020-03-31
NCT02765243 Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT02765243 Recruiting Zhujiang Hospital 2019-05-12
NCT02761915 A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART) https://ClinicalTrials.gov/show/NCT02761915 Recruiting Cancer Research UK 2023-02-28
NCT02748135 A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma https://ClinicalTrials.gov/show/NCT02748135 Recruiting Oncurious NV 2022-06-30
NCT02743429 Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT02743429 Active, not recruiting University Medicine Greifswald 2023-12-31
NCT03213678 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03213678 Recruiting National Cancer Institute (NCI) 2024-09-30
NCT02679144 Neuroblastoma Maintenance Therapy Trial https://ClinicalTrials.gov/show/NCT02679144 Recruiting Spectrum Health Hospitals 2021-02-28
NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03213665 Recruiting National Cancer Institute (NCI) 2024-09-30
NCT02650648 Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02650648 Recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT02644460 Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02644460 Recruiting Emory University 2020-12-31
NCT02641314 Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02641314 Recruiting University of Cologne 2020-10-31
NCT02605421 Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02605421 Recruiting Masonic Cancer Center, University of Minnesota 2020-07-31
NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03213652 Recruiting National Cancer Institute (NCI) 2024-09-30
NCT02573896 Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells https://ClinicalTrials.gov/show/NCT02573896 Recruiting New Approaches to Neuroblastoma Therapy Consortium 2021-01-31
NCT03210714 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) https://ClinicalTrials.gov/show/NCT03210714 Recruiting National Cancer Institute (NCI) 2024-12-31
NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) https://ClinicalTrials.gov/show/NCT03155620 Recruiting National Cancer Institute (NCI) 2027-09-30
NCT03721068 Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT03721068 Recruiting UNC Lineberger Comprehensive Cancer Center 2024-06-19
NCT00107289 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma https://ClinicalTrials.gov/show/NCT00107289 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT02559778 Pediatric Precision Laboratory Advanced Neuroblastoma Therapy https://ClinicalTrials.gov/show/NCT02559778 Recruiting Spectrum Health Hospitals 2025-09-30
NCT03541720 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma https://ClinicalTrials.gov/show/NCT03541720 Active, not recruiting St. Jude Children’s Research Hospital 2021-01-01
NCT02035137 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat https://ClinicalTrials.gov/show/NCT02035137 Active, not recruiting New Approaches to Neuroblastoma Therapy Consortium 2020-01-31
NCT00840047 Methionine PET/CT Studies In Patients With Cancer https://ClinicalTrials.gov/show/NCT00840047 Recruiting St. Jude Children’s Research Hospital 2027-07-27
NCT02536183 A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02536183 Recruiting Children’s National Research Institute 2020-10-31
NCT02508038 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors https://ClinicalTrials.gov/show/NCT02508038 Recruiting University of Wisconsin, Madison 2021-05-31
NCT02452554 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma https://ClinicalTrials.gov/show/NCT02452554 Active, not recruiting Children’s Oncology Group 2017-06-30
NCT02444884 MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02444884 Completed Children’s Oncology Group 2011-12-31
NCT02441088 Theranostics: 68GaDOTATOC and 90YDOTATOC https://ClinicalTrials.gov/show/NCT02441088 Active, not recruiting University of Iowa 2020-01-31
NCT02441062 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT02441062 Completed University of Iowa 2020-01-20
NCT02395666 Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission https://ClinicalTrials.gov/show/NCT02395666 Active, not recruiting Spectrum Health Hospitals 2018-03-01
NCT02390843 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors https://ClinicalTrials.gov/show/NCT02390843 Completed Emory University 2019-09-22
NCT02311621 Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 https://ClinicalTrials.gov/show/NCT02311621 Recruiting Seattle Children’s Hospital 2022-11-30
NCT02308527 Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children https://ClinicalTrials.gov/show/NCT02308527 Recruiting University of Birmingham 2021-07-31
NCT02307630 PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study https://ClinicalTrials.gov/show/NCT02307630 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-11-30
NCT02304458 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas https://ClinicalTrials.gov/show/NCT02304458 Active, not recruiting National Cancer Institute (NCI) 2021-01-31
NCT02298348 Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT02298348 Active, not recruiting New Approaches to Neuroblastoma Therapy Consortium 2020-07-31
NCT02245997 Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02245997 Recruiting Memorial Sloan Kettering Cancer Center 2021-09-30
NCT02176967 Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02176967 Recruiting Children’s Oncology Group 2025-09-30
NCT02173093 Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma https://ClinicalTrials.gov/show/NCT02173093 Recruiting University of Virginia 2019-12-31
NCT02169609 Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma https://ClinicalTrials.gov/show/NCT02169609 Active, not recruiting Fundació Sant Joan de Déu 2019-05-31
NCT02163356 Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma https://ClinicalTrials.gov/show/NCT02163356 Completed South Plains Oncology Consortium 2018-05-31
NCT02162732 Molecular-Guided Therapy for Childhood Cancer https://ClinicalTrials.gov/show/NCT02162732 Active, not recruiting Spectrum Health Hospitals 2020-06-30
NCT02130869 A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT02130869 Completed St. Jude Children’s Research Hospital 2017-12-20
NCT02112617 Phase II Study of Proton Radiation Therapy for Neuroblastoma https://ClinicalTrials.gov/show/NCT02112617 Recruiting Massachusetts General Hospital 2024-03-31
NCT02100930 Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT02100930 Completed Memorial Sloan Kettering Cancer Center 2019-03-07
NCT02100891 Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors https://ClinicalTrials.gov/show/NCT02100891 Recruiting Medical College of Wisconsin 2020-12-31
NCT02095132 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02095132 Active, not recruiting National Cancer Institute (NCI) 2021-04-30
NCT02076906 MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors https://ClinicalTrials.gov/show/NCT02076906 Recruiting Children’s National Research Institute 2020-10-31
NCT01313936 High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT01313936 Completed University of California, San Francisco 2014-05-31
NCT01305200 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01305200 Completed Children’s Oncology Group 2015-06-30
NCT01295762 Immunomonitoring of Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT01295762 Active, not recruiting Centre Leon Berard 2019-03-31
NCT01288573 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone https://ClinicalTrials.gov/show/NCT01288573 Completed Sanofi 2017-05-09
NCT02043899 A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma https://ClinicalTrials.gov/show/NCT02043899 Active, not recruiting Cancer Research UK 2020-11-30
NCT02030964 N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan https://ClinicalTrials.gov/show/NCT02030964 Active, not recruiting New Approaches to Neuroblastoma Therapy Consortium 2020-06-30
NCT02013336 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors https://ClinicalTrials.gov/show/NCT02013336 Recruiting South Plains Oncology Consortium 2020-12-31
NCT01962103 Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01962103 Completed Celgene 2017-12-05
NCT01953900 iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma https://ClinicalTrials.gov/show/NCT01953900 Active, not recruiting Baylor College of Medicine 2021-04-30
NCT01875601 NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT01875601 Completed National Institutes of Health Clinical Center (CC) 2015-09-08
NCT01869725 Ga-DOTATOC Versus Octreoscan + CT https://ClinicalTrials.gov/show/NCT01869725 Completed University of Iowa 2018-12-26
NCT01868269 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) https://ClinicalTrials.gov/show/NCT01868269 Recruiting Institut Curie 2027-02-28
NCT01857934 Therapy for Children With Advanced Stage Neuroblastoma https://ClinicalTrials.gov/show/NCT01857934 Active, not recruiting St. Jude Children’s Research Hospital 2021-01-31
NCT01850888 MIBG for Refractory Neuroblastoma and Pheochromocytoma https://ClinicalTrials.gov/show/NCT01850888 Recruiting Masonic Cancer Center, University of Minnesota 2022-12-31
NCT01822652 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN https://ClinicalTrials.gov/show/NCT01822652 Active, not recruiting Baylor College of Medicine 2015-12-31
NCT01807468 Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors https://ClinicalTrials.gov/show/NCT01807468 Active, not recruiting Samsung Medical Center 2015-12-31
NCT01802567 Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer https://ClinicalTrials.gov/show/NCT01802567 Active, not recruiting Spectrum Health Hospitals 2019-12-31
NCT01802138 A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT01802138 Completed Seoul National University Hospital 2016-06-30
NCT01798004 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01798004 Active, not recruiting Children’s Oncology Group 2015-07-28
NCT01767194 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT01767194 Completed National Cancer Institute (NCI) 2018-06-30
NCT01757626 Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01757626 Recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT01728155 European Low and Intermediate Risk Neuroblastoma Protocol https://ClinicalTrials.gov/show/NCT01728155 Recruiting Instituto de Investigacion Sanitaria La Fe 2021-12-31
NCT01713439 Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL https://ClinicalTrials.gov/show/NCT01713439 Completed Baylor College of Medicine 2001-01-31
NCT01711554 Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT01711554 Active, not recruiting National Cancer Institute (NCI) 2018-09-14
NCT01704872 ch14.18/CHO Bridging Study https://ClinicalTrials.gov/show/NCT01704872 Completed St. Anna Kinderkrebsforschung 2006-02-28
NCT01704716 High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) https://ClinicalTrials.gov/show/NCT01704716 Recruiting St. Anna Kinderkrebsforschung 2019-11-30
NCT01701479 Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) https://ClinicalTrials.gov/show/NCT01701479 Active, not recruiting St. Anna Kinderkrebsforschung 2020-12-31
NCT01625351 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas https://ClinicalTrials.gov/show/NCT01625351 Active, not recruiting St. Jude Children’s Research Hospital 2020-09-18
NCT01619865 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors https://ClinicalTrials.gov/show/NCT01619865 Active, not recruiting University of Iowa 2017-08-27
NCT01606878 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT01606878 Completed Children’s Oncology Group 2018-12-31
NCT01601535 Study of MLN8237 in Combination With Irinotecan and Temozolomide https://ClinicalTrials.gov/show/NCT01601535 Completed New Approaches to Neuroblastoma Therapy Consortium 2018-07-25
NCT01598454 Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides https://ClinicalTrials.gov/show/NCT01598454 Completed Laboratorio Elea Phoenix S.A. 2014-03-31
NCT01592045 ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01592045 Completed United Therapeutics 2014-06-30
NCT01586260 Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission https://ClinicalTrials.gov/show/NCT01586260 Active, not recruiting Spectrum Health Hospitals 2021-04-26
NCT01576692 Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT01576692 Completed St. Jude Children’s Research Hospital 2014-10-31
NCT01526603 High Dose Chemotherapy and Autologous Transplant for Neuroblastoma https://ClinicalTrials.gov/show/NCT01526603 Recruiting Masonic Cancer Center, University of Minnesota 2021-02-28
NCT01518413 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT01518413 Completed Children’s National Research Institute 2015-01-31
NCT01492673 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma https://ClinicalTrials.gov/show/NCT01492673 Completed Memorial Sloan Kettering Cancer Center 2018-10-31
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01467986 Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01467986 Recruiting University of Regensburg 2020-09-30
NCT01462396 Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors https://ClinicalTrials.gov/show/NCT01462396 Completed Children’s Mercy Hospital Kansas City 2015-12-31
NCT01460901 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT01460901 Completed Children’s Mercy Hospital Kansas City 2015-01-31
NCT01445379 Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer https://ClinicalTrials.gov/show/NCT01445379 Completed National Institutes of Health Clinical Center (CC) 2014-04-18
NCT01419834 Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors https://ClinicalTrials.gov/show/NCT01419834 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-08-31
NCT01355679 Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT01355679 Completed Spectrum Health Hospitals 2013-09-30
NCT01334515 Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT01334515 Completed Children’s Oncology Group 2013-12-31
NCT01331135 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors https://ClinicalTrials.gov/show/NCT01331135 Completed Emory University 2017-08-09
NCT04308330 Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies https://ClinicalTrials.gov/show/NCT04308330 Recruiting New York Medical College 2021-12-17
NCT04239092 9-ING-41 in Pediatric Patients With Refractory Malignancies. https://ClinicalTrials.gov/show/NCT04239092 Recruiting Actuate Therapeutics Inc. 2021-04-30
NCT04239040 GVAX Plus Checkpoint Blockade in Neuroblastoma https://ClinicalTrials.gov/show/NCT04239040 Recruiting Dana-Farber Cancer Institute 2027-01-01
NCT04221035 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) https://ClinicalTrials.gov/show/NCT04221035 Recruiting Gustave Roussy, Cancer Campus, Grand Paris 2026-11-30
NCT04049864 DNA Vaccination Against Neuroblastoma https://ClinicalTrials.gov/show/NCT04049864 Recruiting Belarusian Research Center for Pediatric Oncology, Hematology and Immunology 2021-12-31
NCT04040088 An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors https://ClinicalTrials.gov/show/NCT04040088 Recruiting Mayo Clinic 2023-07-10
NCT04029688 A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors https://ClinicalTrials.gov/show/NCT04029688 Recruiting Hoffmann-La Roche 2024-05-16
NCT03979651 MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma https://ClinicalTrials.gov/show/NCT03979651 Recruiting Hospices Civils de Lyon 2022-03-31
NCT03860207 Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers https://ClinicalTrials.gov/show/NCT03860207 Recruiting Memorial Sloan Kettering Cancer Center 2022-02-28
NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT03709680 Recruiting Pfizer 2021-02-16
NCT03635632 C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) https://ClinicalTrials.gov/show/NCT03635632 Recruiting Baylor College of Medicine 2022-06-30
NCT03618381 EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults https://ClinicalTrials.gov/show/NCT03618381 Recruiting Seattle Children’s Hospital 2021-06-30
NCT03561259 A Study of Therapeutic Iobenguane (131-I) for Relapsed, High-Risk Neuroblastoma Subjects https://ClinicalTrials.gov/show/NCT03561259 Recruiting Jubilant DraxImage Inc. 2021-03-31
NCT03545542 Investigating the Microbiome and Volatile Organic Compound Profile of Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT03545542 Recruiting Medical University of Graz 2022-06-30
NCT03503864 Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma https://ClinicalTrials.gov/show/NCT03503864 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2029-12-30
NCT03496402 Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) https://ClinicalTrials.gov/show/NCT03496402 Recruiting Institut Curie 2025-04-01
NCT03478462 Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma https://ClinicalTrials.gov/show/NCT03478462 Recruiting Cellectar Biosciences, Inc. 2020-09-30
NCT03434262 SJDAWN: St. Jude Children’s Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors https://ClinicalTrials.gov/show/NCT03434262 Recruiting St. Jude Children’s Research Hospital 2025-02-28
NCT01241162 Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma https://ClinicalTrials.gov/show/NCT01241162 Completed University of Louisville 2016-10-31
NCT01222780 To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer https://ClinicalTrials.gov/show/NCT01222780 Completed Acrotech Biopharma LLC 2014-12-31
NCT01208454 Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT01208454 Completed National Cancer Institute (NCI) 2014-09-30
NCT01192555 Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01192555 Active, not recruiting Baylor College of Medicine 2012-07-31
NCT01183897 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow https://ClinicalTrials.gov/show/NCT01183897 Completed Memorial Sloan Kettering Cancer Center 2018-09-25
NCT01183429 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01183429 Completed Memorial Sloan Kettering Cancer Center 2018-09-13
NCT01183416 High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation https://ClinicalTrials.gov/show/NCT01183416 Completed Memorial Sloan Kettering Cancer Center 2018-10-31
NCT01175356 Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin https://ClinicalTrials.gov/show/NCT01175356 Completed Children’s Oncology Group 2016-09-28
NCT01169584 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients https://ClinicalTrials.gov/show/NCT01169584 Completed SillaJen, Inc. 2012-03-31
NCT01154816 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01154816 Completed Children’s Oncology Group 2015-12-31
NCT01132911 A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas https://ClinicalTrials.gov/show/NCT01132911 Completed National Institutes of Health Clinical Center (CC) 2011-04-13
NCT01125800 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB https://ClinicalTrials.gov/show/NCT01125800 Completed Novartis 2014-10-31
NCT01114555 Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT01114555 Completed Memorial Sloan Kettering Cancer Center 2018-11-02
NCT01095926 Pharmacokinetic Study of Doxorubicin in Children With Cancer https://ClinicalTrials.gov/show/NCT01095926 Completed University Hospital Muenster 2013-02-28
NCT01059071 Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide https://ClinicalTrials.gov/show/NCT01059071 Completed Spectrum Health Hospitals 2014-10-31
NCT01048892 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features https://ClinicalTrials.gov/show/NCT01048892 Completed Children’s Oncology Group 2013-06-30
NCT00960739 Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma https://ClinicalTrials.gov/show/NCT00960739 Completed Centre Oscar Lambret 2016-03-31
NCT00939770 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma https://ClinicalTrials.gov/show/NCT00939770 Completed Children’s Oncology Group 2018-12-31
NCT00931931 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors https://ClinicalTrials.gov/show/NCT00931931 Completed Nationwide Children’s Hospital 2018-03-19
NCT00923351 Therapy to Treat Ewing’s Sarcoma, Rhabdomyosarcoma or Neuroblastoma https://ClinicalTrials.gov/show/NCT00923351 Completed National Institutes of Health Clinical Center (CC) 2012-08-30
NCT00918320 Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours https://ClinicalTrials.gov/show/NCT00918320 Completed Gustave Roussy, Cancer Campus, Grand Paris 2013-10-31
NCT00911560 Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00911560 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT00885326 N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00885326 Completed New Approaches to Neuroblastoma Therapy Consortium 2014-04-30
NCT00877110 Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00877110 Completed Memorial Sloan Kettering Cancer Center 2019-01-07
NCT00867568 TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma https://ClinicalTrials.gov/show/NCT00867568 Completed Spectrum Health Hospitals 2011-09-30
NCT02139397 Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT02139397 Active, not recruiting Spectrum Health Hospitals 2020-12-31
NCT00831844 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00831844 Completed National Cancer Institute (NCI) 2013-04-30
NCT01662804 Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors https://ClinicalTrials.gov/show/NCT01662804 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-08
NCT01386619 NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) https://ClinicalTrials.gov/show/NCT01386619 Completed University Hospital, Basel, Switzerland 2011-03-31
NCT03332667 MIBG With Dinutuximab https://ClinicalTrials.gov/show/NCT03332667 Recruiting New Approaches to Neuroblastoma Therapy Consortium 2021-09-30
NCT02107963 A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors https://ClinicalTrials.gov/show/NCT02107963 Completed National Institutes of Health Clinical Center (CC) 2016-08-15
NCT01041638 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01041638 Active, not recruiting National Cancer Institute (NCI) 2014-04-14
NCT00793845 Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00793845 Completed Samsung Medical Center 2015-01-31
NCT00793351 Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation https://ClinicalTrials.gov/show/NCT00793351 Completed Samsung Medical Center 2013-11-30
NCT00790413 Haploidentical Stem Cell Transplantation in Neuroblastoma https://ClinicalTrials.gov/show/NCT00790413 Active, not recruiting Lund University Hospital 2020-12-31
NCT00788125 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors https://ClinicalTrials.gov/show/NCT00788125 Active, not recruiting City of Hope Medical Center 2023-09-30
NCT00782145 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families https://ClinicalTrials.gov/show/NCT00782145 Completed Tufts Medical Center 2011-06-30
NCT00754286 A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer https://ClinicalTrials.gov/show/NCT00754286 Completed Albert Einstein College of Medicine 2011-07-31
NCT00743496 A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma https://ClinicalTrials.gov/show/NCT00743496 Completed St. Jude Children’s Research Hospital 2014-04-01
NCT00726934 The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients https://ClinicalTrials.gov/show/NCT00726934 Completed Indiana University 2017-01-31
NCT00716976 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy https://ClinicalTrials.gov/show/NCT00716976 Completed Children’s Oncology Group 2015-04-30
NCT00703222 A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells https://ClinicalTrials.gov/show/NCT00703222 Active, not recruiting Baylor College of Medicine 2011-05-31
NCT00659984 N2007-01: Ultratraceâ„¢ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00659984 Completed Molecular Insight Pharmaceuticals, Inc. 2010-08-31
NCT00646230 N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma https://ClinicalTrials.gov/show/NCT00646230 Completed Children’s Hospital Los Angeles 2012-03-31
NCT00644696 Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00644696 Completed University of Michigan Rogel Cancer Center 2012-07-31
NCT00601003 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma https://ClinicalTrials.gov/show/NCT00601003 Active, not recruiting Spectrum Health Hospitals 2020-05-01
NCT00638898 Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor https://ClinicalTrials.gov/show/NCT00638898 Active, not recruiting City of Hope Medical Center 2020-09-01
NCT00578864 Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00578864 Completed Baylor College of Medicine 2009-07-31
NCT00567567 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00567567 Active, not recruiting Children’s Oncology Group 2015-02-27
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00520936 A Study of Pemetrexed in Children With Recurrent Cancer https://ClinicalTrials.gov/show/NCT00520936 Completed Eli Lilly and Company 2010-02-28
NCT00509353 N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00509353 Completed Children’s Hospital Los Angeles 2010-10-31
NCT00503724 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors https://ClinicalTrials.gov/show/NCT00503724 Completed Pediatric Brain Tumor Consortium 2010-05-31
NCT00499616 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00499616 Active, not recruiting Children’s Oncology Group 2014-06-30
NCT00492167 Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma https://ClinicalTrials.gov/show/NCT00492167 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-08-31
NCT00486564 Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00486564 Completed University of Vermont 2007-11-30
NCT00471679 Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00471679 Completed Memorial Sloan Kettering Cancer Center 2010-02-28
NCT00450827 Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00450827 Completed Memorial Sloan Kettering Cancer Center 2015-08-31
NCT00450307 Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT00450307 Completed Memorial Sloan Kettering Cancer Center 2013-04-30
NCT00445965 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer https://ClinicalTrials.gov/show/NCT00445965 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT00436852 ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment https://ClinicalTrials.gov/show/NCT00436852 Completed Children’s Oncology Group 2010-09-01
NCT00436657 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00436657 Completed M.D. Anderson Cancer Center 2011-04-30
NCT00410657 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00410657 Completed Fred Hutchinson Cancer Research Center 2006-11-30
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00407433 Clinical Studies of Gemcitabine-Oxaliplatin https://ClinicalTrials.gov/show/NCT00407433 Completed Gustave Roussy, Cancer Campus, Grand Paris NA
NCT00405327 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00405327 Completed University of Michigan Rogel Cancer Center 2009-06-30
NCT01019850 N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT01019850 Completed New Approaches to Neuroblastoma Therapy Consortium 2014-12-31
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00365755 Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma https://ClinicalTrials.gov/show/NCT00365755 Completed National Cancer Institute (NCI) NA
NCT00357500 Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer https://ClinicalTrials.gov/show/NCT00357500 Completed Dana-Farber Cancer Institute 2013-02-28
NCT00336531 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00336531 Completed Samsung Medical Center 2008-06-30
NCT00331643 Ixabepilone in Treating Young Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00331643 Completed National Cancer Institute (NCI) 2007-10-31
NCT00311584 Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT00311584 Completed Children’s Oncology Group 2009-03-31
NCT00309907 Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00309907 Completed Children’s Oncology Group 2011-09-30
NCT00303940 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors https://ClinicalTrials.gov/show/NCT00303940 Completed National Institutes of Health Clinical Center (CC) NA
NCT00295919 N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma https://ClinicalTrials.gov/show/NCT00295919 Completed Children’s Hospital Los Angeles 2014-03-31
NCT00293384 Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00293384 Completed Barbara Ann Karmanos Cancer Institute 2009-06-30
NCT00293319 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT00293319 Completed University of California, San Francisco 2006-03-31
NCT00276679 Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00276679 Completed National Cancer Institute (NCI) NA
NCT00253435 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00253435 Completed Children’s Hospital Los Angeles 2012-12-31
NCT00217412 Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia https://ClinicalTrials.gov/show/NCT00217412 Completed National Cancer Institute (NCI) 2009-09-30
NCT00206388 Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement https://ClinicalTrials.gov/show/NCT00206388 Completed Baylor College of Medicine 2008-04-30
NCT00187109 Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy https://ClinicalTrials.gov/show/NCT00187109 Completed St. Jude Children’s Research Hospital 2007-02-28
NCT00186862 Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00186862 Completed St. Jude Children’s Research Hospital 2000-04-30
NCT00186849 Therapy for Children With Advanced Stage High Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00186849 Completed St. Jude Children’s Research Hospital 2001-04-30
NCT00165139 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas https://ClinicalTrials.gov/show/NCT00165139 Completed Dana-Farber Cancer Institute 2000-11-30
NCT00152126 Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas https://ClinicalTrials.gov/show/NCT00152126 Completed St. Jude Children’s Research Hospital 2005-08-31
NCT00135135 Therapy for Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT00135135 Completed St. Jude Children’s Research Hospital 2007-06-30
NCT00132158 ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00132158 Completed St. Jude Children’s Research Hospital 2011-10-31
NCT00126412 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma https://ClinicalTrials.gov/show/NCT00126412 Completed GE Healthcare 2006-09-27
NCT00118326 Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease https://ClinicalTrials.gov/show/NCT00118326 Completed Fred Hutchinson Cancer Research Center NA
NCT00112645 Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00112645 Completed National Cancer Institute (NCI) 2010-04-30
NCT00109993 Campath-1H + FK506 and Methylprednisolone for GVHD https://ClinicalTrials.gov/show/NCT00109993 Completed Case Comprehensive Cancer Center 2006-06-30
NCT00089245 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer https://ClinicalTrials.gov/show/NCT00089245 Active, not recruiting Y-mAbs Therapeutics 2019-07-01
NCT00101270 Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00101270 Completed National Cancer Institute (NCI) 2007-09-30
NCT00098865 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma https://ClinicalTrials.gov/show/NCT00098865 Completed Dana-Farber Cancer Institute 2010-06-30
NCT00093821 Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors https://ClinicalTrials.gov/show/NCT00093821 Completed National Cancer Institute (NCI) 2007-08-31
NCT00093353 N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma https://ClinicalTrials.gov/show/NCT00093353 Completed Children’s Hospital Los Angeles 2006-07-31
NCT00002543 Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin’s Lymphoma, or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00002543 Completed National Cancer Institute (NCI) NA
NCT00091182 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment https://ClinicalTrials.gov/show/NCT00091182 Completed National Cancer Institute (NCI) 2006-02-28
NCT00002730 Chemotherapy in Treating Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT00002730 Completed Children’s Hospital Los Angeles NA
NCT00002458 Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission https://ClinicalTrials.gov/show/NCT00002458 Completed Memorial Sloan Kettering Cancer Center 2001-09-30
NCT00002634 Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00002634 Completed Memorial Sloan Kettering Cancer Center 2004-09-30
NCT00089258 Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment https://ClinicalTrials.gov/show/NCT00089258 Completed Memorial Sloan Kettering Cancer Center 2006-11-30
NCT00003661 Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00003661 Completed Roswell Park Cancer Institute 1999-11-30
NCT00085930 Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients https://ClinicalTrials.gov/show/NCT00085930 Active, not recruiting Baylor College of Medicine 2010-01-31
NCT00002740 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma https://ClinicalTrials.gov/show/NCT00002740 Completed Children’s Oncology Group 2004-03-31
NCT00003846 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors https://ClinicalTrials.gov/show/NCT00003846 Completed Children’s Oncology Group 2004-10-31
NCT00082758 hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00082758 Completed Children’s Oncology Group 2008-02-29
NCT00082654 Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients https://ClinicalTrials.gov/show/NCT00082654 Completed Fred Hutchinson Cancer Research Center 2004-10-31
NCT00083135 N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00083135 Completed Children’s Hospital Los Angeles 2006-02-28
NCT00002803 Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma https://ClinicalTrials.gov/show/NCT00002803 Completed National Cancer Institute (NCI) NA
NCT00002802 Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT00002802 Completed National Cancer Institute (NCI) NA
NCT00003887 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00003887 Completed Fred Hutchinson Cancer Research Center NA
NCT00010283 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon https://ClinicalTrials.gov/show/NCT00010283 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00080873 Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00080873 Completed Children’s Oncology Group 2006-11-30
NCT00003107 Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors https://ClinicalTrials.gov/show/NCT00003107 Completed Indiana University NA
NCT00007813 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors https://ClinicalTrials.gov/show/NCT00007813 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2005-02-01
NCT00002825 Docetaxel in Treating Children With Recurrent Solid Tumors https://ClinicalTrials.gov/show/NCT00002825 Completed National Cancer Institute (NCI) 2004-12-31
NCT00003425 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect https://ClinicalTrials.gov/show/NCT00003425 Completed University of Kentucky 2002-07-31
NCT00077454 Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00077454 Completed National Cancer Institute (NCI) 2007-09-30
NCT00004157 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin’s Lymphoma, Hodgkin’s Disease, Breast Cancer, or Other Solid Tumors https://ClinicalTrials.gov/show/NCT00004157 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00002748 Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT00002748 Completed St. Jude Children’s Research Hospital 2007-08-31
NCT00075634 Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma https://ClinicalTrials.gov/show/NCT00075634 Completed National Cancer Institute (NCI) 2007-09-30
NCT00006480 Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00006480 Completed Fred Hutchinson Cancer Research Center NA
NCT00005978 N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00005978 Completed New Approaches to Neuroblastoma Therapy Consortium 2004-12-31
NCT00003191 Fenretinide in Treating Children With Solid Tumors https://ClinicalTrials.gov/show/NCT00003191 Completed National Cancer Institute (NCI) 2005-03-31
NCT00072358 Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00072358 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-12-31
NCT00003141 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors https://ClinicalTrials.gov/show/NCT00003141 Completed Children’s Oncology Group 2007-12-31
NCT00005576 Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT00005576 Completed National Cancer Institute (NCI) 2002-03-31
NCT00003234 Vinorelbine in Treating Children With Recurrent or Refractory Cancers https://ClinicalTrials.gov/show/NCT00003234 Completed Children’s Oncology Group 2006-03-31
NCT00017368 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma https://ClinicalTrials.gov/show/NCT00017368 Completed Children’s Oncology Group 2005-09-30
NCT00070200 Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma https://ClinicalTrials.gov/show/NCT00070200 Completed Children’s Oncology Group 2006-09-30
NCT00066599 Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy https://ClinicalTrials.gov/show/NCT00066599 Completed National Cancer Institute (NCI) NA
NCT00064311 Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00064311 Completed National Institutes of Health Clinical Center (CC) NA
NCT00062855 Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00062855 Completed Baylor College of Medicine 2001-08-31
NCT00003408 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer https://ClinicalTrials.gov/show/NCT00003408 Completed National Cancer Institute (NCI) NA
NCT00003203 Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors https://ClinicalTrials.gov/show/NCT00003203 Completed Children’s Oncology Group 2007-10-31
NCT00060372 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer https://ClinicalTrials.gov/show/NCT00060372 Completed National Cancer Institute (NCI) 2008-04-30
NCT00030667 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood https://ClinicalTrials.gov/show/NCT00030667 Completed National Cancer Institute (NCI) 2005-12-31
NCT00003484 Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors https://ClinicalTrials.gov/show/NCT00003484 Completed Duke University 2003-11-30
NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma https://ClinicalTrials.gov/show/NCT00053326 Completed National Cancer Institute (NCI) 2006-03-31
NCT00053118 Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer https://ClinicalTrials.gov/show/NCT00053118 Completed Roswell Park Cancer Institute 2004-07-31
NCT00004078 Irinotecan in Treating Children With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00004078 Completed Children’s Oncology Group 2007-10-31
NCT00049023 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00049023 Completed University of Iowa 2011-08-31
NCT00040911 Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00040911 Completed Children’s Oncology Group 2009-10-31
NCT00040872 Multiple Therapies in Treating Patients With Advanced Neuroblastoma https://ClinicalTrials.gov/show/NCT00040872 Completed Memorial Sloan Kettering Cancer Center 2007-01-31
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00037011 Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma https://ClinicalTrials.gov/show/NCT00037011 Completed Memorial Sloan Kettering Cancer Center 2005-01-31
NCT00036959 ABT-751 in Treating Young Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT00036959 Completed National Institutes of Health Clinical Center (CC) 2010-02-28
NCT00030108 Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven’t Responded to Therapy https://ClinicalTrials.gov/show/NCT00030108 Completed National Institutes of Health Clinical Center (CC) 2010-03-31
NCT00026312 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00026312 Active, not recruiting National Cancer Institute (NCI) 2012-01-12
NCT00025649 Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma https://ClinicalTrials.gov/show/NCT00025649 Completed National Cancer Institute (NCI) NA
NCT00025623 Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma https://ClinicalTrials.gov/show/NCT00025623 Completed National Cancer Institute (NCI) NA
NCT00025610 Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma https://ClinicalTrials.gov/show/NCT00025610 Completed National Cancer Institute (NCI) NA
NCT00025597 Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma. https://ClinicalTrials.gov/show/NCT00025597 Completed National Cancer Institute (NCI) NA
NCT00025428 Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma https://ClinicalTrials.gov/show/NCT00025428 Completed National Cancer Institute (NCI) NA
NCT00024258 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors https://ClinicalTrials.gov/show/NCT00024258 Completed Memorial Sloan Kettering Cancer Center 2009-05-31
NCT00020527 Caspofungin Acetate in Treating Children With Fever and Neutropenia https://ClinicalTrials.gov/show/NCT00020527 Completed National Cancer Institute (NCI) NA
NCT00020150 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors https://ClinicalTrials.gov/show/NCT00020150 Completed National Cancer Institute (NCI) NA
NCT00017225 Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00017225 Completed National Cancer Institute (NCI) NA
NCT00012181 Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00012181 Completed National Cancer Institute (NCI) 2005-01-31
NCT00006102 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00006102 Completed National Cancer Institute (NCI) 2006-06-30
NCT00005955 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors https://ClinicalTrials.gov/show/NCT00005955 Completed Duke University NA
NCT00005952 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors https://ClinicalTrials.gov/show/NCT00005952 Completed Duke University 2005-11-30
NCT00005835 N99-02: Melphalan and Buthionine Sulfoximine https://ClinicalTrials.gov/show/NCT00005835 Completed New Approaches to Neuroblastoma Therapy Consortium 2014-12-31
NCT00004188 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00004188 Completed Children’s Oncology Group 2007-10-31
NCT00004110 Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00004110 Completed Memorial Sloan Kettering Cancer Center 2004-09-30
NCT00003750 Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors https://ClinicalTrials.gov/show/NCT00003750 Completed Children’s Oncology Group 2005-01-31
NCT00003737 Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma https://ClinicalTrials.gov/show/NCT00003737 Completed Memorial Sloan Kettering Cancer Center 2006-09-30
NCT00003461 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors https://ClinicalTrials.gov/show/NCT00003461 Completed Duke University 2005-02-28
NCT00003119 Surgery in Treating Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT00003119 Completed Children’s Oncology Group 2006-03-31
NCT00003093 Combination Chemotherapy in Treating Children With Neuroblastoma https://ClinicalTrials.gov/show/NCT00003093 Completed Children’s Oncology Group 2006-09-30
NCT00003023 Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer https://ClinicalTrials.gov/show/NCT00003023 Completed Memorial Sloan Kettering Cancer Center 2005-01-31
NCT00003022 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer https://ClinicalTrials.gov/show/NCT00003022 Completed Memorial Sloan Kettering Cancer Center 2005-01-31
NCT00002560 Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma https://ClinicalTrials.gov/show/NCT00002560 Completed Memorial Sloan Kettering Cancer Center 2005-04-30
NCT00002515 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer https://ClinicalTrials.gov/show/NCT00002515 Completed Memorial Sloan Kettering Cancer Center 2005-04-30
NCT00001565 Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy https://ClinicalTrials.gov/show/NCT00001565 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001509 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms’ Tumor https://ClinicalTrials.gov/show/NCT00001509 Completed National Institutes of Health Clinical Center (CC) NA
NCT00048386 Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy https://ClinicalTrials.gov/show/NCT00048386 Completed Baylor College of Medicine 2004-12-31
NCT00084422 N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT00084422 Completed New Approaches to Neuroblastoma Therapy Consortium 2009-09-30
NCT00028522 R(+)XK469 in Treating Patients With Advanced Neuroblastoma https://ClinicalTrials.gov/show/NCT00028522 Completed National Cancer Institute (NCI) 2009-09-30
NCT00001335 New Therapeutic Strategies for Patients With Ewing’s Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma https://ClinicalTrials.gov/show/NCT00001335 Completed National Institutes of Health Clinical Center (CC) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03382158 International PPB/DICER1 Registry https://ClinicalTrials.gov/show/NCT03382158 Recruiting Children’s Hospitals and Clinics of Minnesota 2023-12-06
NCT03057626 Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT03057626 Recruiting Children’s Oncology Group 2020-09-30
NCT03050268 Familial Investigations of Childhood Cancer Predisposition https://ClinicalTrials.gov/show/NCT03050268 Recruiting St. Jude Children’s Research Hospital 2037-03-31
NCT02868268 Neuroblastoma Precision Trial https://ClinicalTrials.gov/show/NCT02868268 Recruiting New Approaches to Neuroblastoma Therapy Consortium 2020-01-31
NCT01005654 Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms https://ClinicalTrials.gov/show/NCT01005654 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00026780 Eligibility Screening for a NCI Pediatric Oncology Branch Research Study https://ClinicalTrials.gov/show/NCT00026780 Enrolling by invitation National Institutes of Health Clinical Center (CC) NA
NCT02558244 Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study https://ClinicalTrials.gov/show/NCT02558244 Recruiting Assiut University 2020-09-30
NCT02282735 Parental Decision-Making for Children With Relapsed Neuroblastoma https://ClinicalTrials.gov/show/NCT02282735 Active, not recruiting Dana-Farber Cancer Institute 2019-04-30
NCT02159443 Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody https://ClinicalTrials.gov/show/NCT02159443 Active, not recruiting St. Jude Children’s Research Hospital 2019-10-22
NCT01638572 Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma https://ClinicalTrials.gov/show/NCT01638572 Completed National Taiwan University Hospital 2011-12-31
NCT01589341 Studying Chromosomes in Samples From Younger Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01589341 Completed Children’s Oncology Group 2012-08-31
NCT01587300 Neuroblastoma Biology Study https://ClinicalTrials.gov/show/NCT01587300 Recruiting New Approaches to Neuroblastoma Therapy Consortium 2020-12-31
NCT01553448 Studying Gene Expression in Samples From Younger Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01553448 Completed Children’s Oncology Group 2016-05-31
NCT01520233 Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01520233 Completed Children’s Oncology Group 2016-05-31
NCT01510600 Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01510600 Completed Children’s Oncology Group 2016-05-31
NCT01493830 Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01493830 Completed Children’s Oncology Group 2016-07-31
NCT01482741 Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging https://ClinicalTrials.gov/show/NCT01482741 Completed Memorial Sloan Kettering Cancer Center 2015-06-30
NCT01418495 Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma https://ClinicalTrials.gov/show/NCT01418495 Completed National Cancer Institute (NCI) NA
NCT01407731 Protein Expression in Human Neuroblastoma Tumor Samples https://ClinicalTrials.gov/show/NCT01407731 Completed Children’s Oncology Group 2016-05-31
NCT01387724 Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma https://ClinicalTrials.gov/show/NCT01387724 Completed Children’s Oncology Group 2016-05-31
NCT01358617 Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01358617 Completed Children’s Oncology Group 2011-08-31
NCT01358604 Biomarkers in Samples From Young Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01358604 Completed Children’s Oncology Group 2016-04-30
NCT01353300 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer https://ClinicalTrials.gov/show/NCT01353300 Completed Children’s Oncology Group 2016-07-31
NCT03947346 Biomarkers of Renal Dysfunction in Neuroblastoma Survivors https://ClinicalTrials.gov/show/NCT03947346 Enrolling by invitation Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03583528 DOTATOC PET/CT for Imaging NET Patients https://ClinicalTrials.gov/show/NCT03583528 Recruiting British Columbia Cancer Agency 2023-12-31
NCT03517280 Nutritional Status in Neuroblastoma in Sao Paolo, Brazil https://ClinicalTrials.gov/show/NCT03517280 Recruiting Columbia University 2022-01-01
NCT01169376 Biomarkers in Young Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01169376 Completed Children’s Oncology Group 2016-05-31
NCT01121419 The Role of IMP3 Expression in Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT01121419 Completed National Taiwan University Hospital 2009-01-31
NCT01119560 Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) https://ClinicalTrials.gov/show/NCT01119560 Completed Children’s Oncology Group 2018-12-31
NCT01109394 Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies https://ClinicalTrials.gov/show/NCT01109394 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01109238 A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma https://ClinicalTrials.gov/show/NCT01109238 Completed Spectrum Health Hospitals 2010-07-31
NCT01075360 The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its Relationship With MYCN Expression https://ClinicalTrials.gov/show/NCT01075360 Completed National Taiwan University Hospital 2008-10-31
NCT01058798 The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma https://ClinicalTrials.gov/show/NCT01058798 Completed National Taiwan University Hospital 2008-02-29
NCT00996710 Genomic Structural Variation in Cancer Susceptibility https://ClinicalTrials.gov/show/NCT00996710 Enrolling by invitation Memorial Sloan Kettering Cancer Center 2020-10-31
NCT00958659 Study of Specimens From Young Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00958659 Completed Children’s Oncology Group 2016-05-31
NCT00923650 Informed Consent in Pediatric Cancer Trials https://ClinicalTrials.gov/show/NCT00923650 Completed National Institutes of Health Clinical Center (CC) NA
NCT00907920 Studying Tumor Samples From Young Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00907920 Completed Children’s Oncology Group 2008-12-31
NCT00904241 Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma https://ClinicalTrials.gov/show/NCT00904241 Recruiting Children’s Oncology Group 2100-01-01
NCT00900406 Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00900406 Completed Vanderbilt-Ingram Cancer Center 2010-03-31
NCT00898755 Collecting and Storing Tissue From Young Patients With Cancer https://ClinicalTrials.gov/show/NCT00898755 Completed Children’s Oncology Group 2008-07-17
NCT00898391 Study of DNA in Blood Samples From Patients With Neuroblastoma https://ClinicalTrials.gov/show/NCT00898391 Completed Children’s Oncology Group 2016-05-31
NCT04017104 Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging https://ClinicalTrials.gov/show/NCT04017104 Recruiting British Columbia Cancer Agency 2022-08-01
NCT03686566 Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics] https://ClinicalTrials.gov/show/NCT03686566 Active, not recruiting University of Texas Southwestern Medical Center 2020-07-31
NCT00695279 Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products https://ClinicalTrials.gov/show/NCT00695279 Recruiting St. Jude Children’s Research Hospital 2036-12-31
NCT00608452 Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers https://ClinicalTrials.gov/show/NCT00608452 Completed Memorial Sloan Kettering Cancer Center 2009-11-30
NCT00590096 I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma https://ClinicalTrials.gov/show/NCT00590096 Completed Children’s Hospital Medical Center, Cincinnati 2008-12-31
NCT00588068 Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome https://ClinicalTrials.gov/show/NCT00588068 Recruiting Memorial Sloan Kettering Cancer Center 2021-09-30
NCT00445718 Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging https://ClinicalTrials.gov/show/NCT00445718 Completed Children’s Oncology Group 2013-01-31
NCT00436696 Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions https://ClinicalTrials.gov/show/NCT00436696 Completed Children’s Oncology Group 2016-05-05
NCT00002485 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer https://ClinicalTrials.gov/show/NCT00002485 Completed Children’s Oncology Group 2003-07-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT01853345 iCAT for Recurrent/Refractory/HR Solid Tumors https://ClinicalTrials.gov/show/NCT01853345 Completed Dana-Farber Cancer Institute 2014-09-30
NCT04253015 A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta https://ClinicalTrials.gov/show/NCT04253015 Active, not recruiting EusaPharma (UK) Limited 2031-10-30
NCT03568669 Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS) https://ClinicalTrials.gov/show/NCT03568669 Recruiting Ann & Robert H Lurie Children’s Hospital of Chicago 2030-12-31